F.H. Investments, Inc.
FDA 503B outsourcing facility
Birmingham, Alabama
Key Takeaways
- FDA-registered 503B outsourcing facility since 2025
- Sterile compounding from bulk substances: Yes
- Last FDA inspection: December 19, 2025
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- May 13, 2025
- Most recent registration
- December 2, 2025
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- December 19, 2025
- NPI
- 1700180668
The FDA last inspected F.H. Investments, Inc. on December 19, 2025. Investigators issued a Form FDA 483 listing inspectional observations at that visit. The FDA has not yet determined whether further action will be taken.
Compounded peptides and GLP-1s
F.H. Investments, Inc. has not assigned NDCs or filed product reports in the most recent FDA reporting periods. 503B outsourcing facilities are a primary supply route for compounded peptides and GLP-1s during FDA-listed shortages; PeptideGrids grades the evidence for each, including Semaglutide, Tirzepatide, BPC-157, Retatrutide. Browse the GLP-1 and therapeutic peptide databases.
Location
7004 CHAMPION BLVD STE 100, Birmingham, AL
Satellite and street imagery via Esri. Open larger map.
Contact
FDA-registered contact: Christopher S. Musser, 1-205-995-0505. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of F.H. Investments, Inc. with the Alabama State Board of Pharmacy.
503B facilities in Alabama
Alabama has 2 FDA-registered 503B outsourcing facilities in the PeptideGrids directory. See all 503B facilities in Alabama.
Frequently asked questions
Is F.H. Investments, Inc. registered with the FDA?
Yes. F.H. Investments, Inc. is a registered 503B outsourcing facility, first registered with the FDA on May 13, 2025 and most recently registered on December 2, 2025.
Has F.H. Investments, Inc. been inspected by the FDA?
The FDA last inspected F.H. Investments, Inc. on December 19, 2025. A Form FDA 483 was issued.
Has F.H. Investments, Inc. had any FDA drug recalls?
No FDA drug recalls are matched to F.H. Investments, Inc. in the openFDA enforcement database.
What does F.H. Investments, Inc. compound?
F.H. Investments, Inc. has not filed product reports with NDC-assigned drugs in the most recent FDA reporting periods.
Where is F.H. Investments, Inc. located?
F.H. Investments, Inc. is located in Birmingham, Alabama (7004 CHAMPION BLVD STE 100).
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by F.H. Investments, Inc.. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.